Beating heart 3D printed by CAS scientists on modified bioprinter

Researchers from the Chinese Academy of Sciences (CAS) have converted a six-axis robotic arm into a 3D bioprinter capable of printing cells from all directions.

Using the modified bioprinter, the researchers were able to fabricate a complex-shaped blood vessel scaffold without causing cell damage or preventing cell growth and function, which are common challenges to current bioprinting methods. The 3D printed vascularized cardiac tissue remained alive and beating for six months, and could demonstrate a feasible method of bioprinting functional tissues and organs in the future.

The team also designed a repeated print-and-culture bioprinting strategy that could generate complex tissues or organs containing blood vessel networks capable of maintaining long-term survival and key functions in the future.

The CAS researchers’ novel bioprinting platform. Image via Bioactive Materials.

3D bioprinting tissues

Over the past decade, there has been significant progress made in the development of viable patient-specific tissues by means of 3D bioprinting technologies. While fully printed organs still remain some way off, several bioprinting firms and research teams have taken notable strides in the right direction.

3D printer manufacturer 3D Systems, for instance, is expanding its bioprinting program after acquiring bioprinting technology developer Volumetric biotechnologies, while bioprinting start-up Brinter is seeking to open up the accessibility of bioprinting with its new entry-level 3D printer, the Brinter Core. Elsewhere, regenerative medicine company CTIBIOTECH has unveiled a new 3D bioprinting platform to deliver personalized medicine for patients with colon cancer.

There have also been regulatory advances in the bioprinting space, with BICO recently being granted two new patents for 3D printing temperature-sensitive bioinks, and regenerative medicine firm Matricelf licensing Tel Aviv University’s patent-pending 3D bioprinting technology for organ and tissue implants. Most recently, bioengineering start-up Trestle Biotherapeutics gained a license for a new 3D bioprinting technology that enables the fabrication of functional human kidney tissues.

Other recent regenerative medicine breakthroughs include new bioinks specifically for bioprinting blood vessels, the successful 3D printing of living brain cells, and a new volumetric 3D printing process capable of fabricating functional bioprinted livers.

The six-axis robot bioprinter brings no damage to cells and supports multi-dimensional cell printing. Image via Bioactive Materials.

The novel bioprinting platform

For their latest study, the CAS researchers sought to overcome current challenges surrounding the incorporation of blood vessel networks during the bioprinting process. Most current technologies rely on immobilizing printed cells by adding artificial biomaterials to the bioinks, which can inhibit cell functionality and the formation of new blood vessels. This in turn reduces the biological function of the printed structure and its long-term survival.

The team started by converting a six-axis robotic arm into a 3D bioprinter to enable cell printing from all directions. To avoid to solidification of biomaterials, the researchers also designed an oil bath-based cell printing system that transforms the printed cells into blood vessel scaffolds by means of hydrophobicity, or the process of repelling water. This meant that the blood vessel scaffolds better maintained their cell activity while also promoting the formation of cell-to-cell contact.

The team used their converted bioprinter and oil bath to design a repeated print-and-culture bioprinting strategy, inspired by natural organ developmental processes. They printed mono and multilayered cells onto the blood vessel scaffold which were cultured for certain intervals in order to induce the formation of cell-to-cell contact and the growth of new blood vessels. Then, the scaffold and already printed cells were subjected to a new round of bioprinting.